Equities Analysts Offer Predictions for SPTX Q2 Earnings

Seaport Therapeutics, Inc. (NASDAQ:SPTX) – Investment analysts at HC Wainwright issued their Q2 2026 earnings per share estimates for shares of Seaport Therapeutics in a research note issued to investors on Wednesday, July 15th. HC Wainwright analyst R. Selvaraju forecasts that the company will post earnings of ($0.96) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $50.00 target price on the stock. HC Wainwright also issued estimates for Seaport Therapeutics’ Q3 2026 earnings at ($0.54) EPS, Q4 2026 earnings at ($0.58) EPS, FY2026 earnings at ($3.25) EPS, Q1 2027 earnings at ($0.61) EPS, Q2 2027 earnings at ($0.64) EPS, Q3 2027 earnings at ($0.66) EPS, Q4 2027 earnings at ($0.69) EPS and FY2027 earnings at ($2.60) EPS.

Seaport Therapeutics (NASDAQ:SPTX) last issued its quarterly earnings data on Monday, June 8th. The company reported ($10.34) EPS for the quarter, beating analysts’ consensus estimates of ($10.64) by $0.30.

A number of other research analysts have also recently weighed in on SPTX. JPMorgan Chase & Co. began coverage on shares of Seaport Therapeutics in a research note on Tuesday, May 26th. They set an “overweight” rating and a $42.00 price objective for the company. Citigroup assumed coverage on Seaport Therapeutics in a research note on Tuesday, May 26th. They issued a “buy” rating and a $35.00 target price on the stock. Wall Street Zen upgraded Seaport Therapeutics to a “hold” rating in a report on Saturday, May 9th. BNP Paribas Exane downgraded Seaport Therapeutics to a “market perform” rating in a research report on Tuesday, May 26th. Finally, Seaport Research Partners set a $50.00 price target on Seaport Therapeutics in a report on Wednesday, July 15th. Five analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Hold” and an average price target of $38.40.

Seaport Therapeutics Trading Up 2.2%

Shares of SPTX opened at $21.00 on Monday. The firm has a market capitalization of $1.12 billion and a PE ratio of -2.03. The business’s 50-day simple moving average is $18.64. Seaport Therapeutics has a 12-month low of $14.85 and a 12-month high of $23.00.

Insider Activity

In other news, Director Robert J. Hombach purchased 13,000 shares of the stock in a transaction dated Monday, June 22nd. The stock was acquired at an average cost of $18.14 per share, for a total transaction of $235,820.00. Following the completion of the acquisition, the director directly owned 13,000 shares in the company, valued at $235,820. This represents a ∞ increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, major shareholder Arch Venture Partners Xii, Llc purchased 1,100,000 shares of the stock in a transaction dated Monday, May 4th. The shares were purchased at an average price of $18.00 per share, with a total value of $19,800,000.00. Following the completion of the acquisition, the insider owned 6,294,951 shares of the company’s stock, valued at approximately $113,309,118. This represents a 21.17% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure.